Who Generates More Revenue? Regeneron Pharmaceuticals, Inc. or Ionis Pharmaceuticals, Inc.

Regeneron leads Ionis in revenue growth over a decade.

__timestampIonis Pharmaceuticals, Inc.Regeneron Pharmaceuticals, Inc.
Wednesday, January 1, 20142141610002819557000
Thursday, January 1, 20152837030004103728000
Friday, January 1, 20163466200004860427000
Sunday, January 1, 20175076660005872227000
Monday, January 1, 20185996740006710800000
Tuesday, January 1, 201911230000007863400000
Wednesday, January 1, 20207290000008497100000
Friday, January 1, 202181000000016071700000
Saturday, January 1, 202258700000012172900000
Sunday, January 1, 202378764700013117200000
Monday, January 1, 202470513800014202000000
Loading chart...

Cracking the code

Revenue Battle: Regeneron vs. Ionis

In the competitive landscape of biotechnology, revenue generation is a key indicator of a company's market strength and innovation prowess. Over the past decade, Regeneron Pharmaceuticals, Inc. has consistently outperformed Ionis Pharmaceuticals, Inc. in terms of revenue. From 2014 to 2023, Regeneron's revenue surged by approximately 365%, peaking at $13.1 billion in 2023. In contrast, Ionis saw a more modest growth of around 268%, reaching $787 million in the same year.

A Decade of Growth

Regeneron's revenue growth is particularly notable in 2021, where it nearly doubled from the previous year, reaching $16 billion. This leap underscores Regeneron's strategic advancements and successful product launches. Meanwhile, Ionis experienced its highest revenue in 2019, with a notable $1.1 billion, before stabilizing in subsequent years.

Conclusion

This data highlights Regeneron's dominant position in the biotech sector, driven by its robust pipeline and strategic market positioning.

Published by
U.S. Securities and Exchange Commission

Source link
sec.gov

Date published
17 Jan 2025